ASBP Latest Press Releases

-- June 12, 2026 --

Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue ACCESS Newswire 8:30 AM

-- May 28, 2026 --

Aspire Biopharma Issues Shareholder Letter ACCESS Newswire 8:30 AM

-- May 27, 2026 --

Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members ACCESS Newswire 8:30 AM

-- May 7, 2026 --

Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio ACCESS Newswire 11:00 AM

-- April 27, 2026 --

Aspire Biopharma Announces $5.0 Million Share Repurchase Program ACCESS Newswire 8:30 AM

-- April 20, 2026 --

Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition ACCESS Newswire 8:30 AM

-- April 17, 2026 --

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo ACCESS Newswire 8:00 AM

-- April 16, 2026 --

Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue ACCESS Newswire 8:30 AM

-- April 15, 2026 --

Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion ACCESS Newswire 8:00 AM

-- March 19, 2026 --

Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion ACCESS Newswire 8:05 AM

-- March 17, 2026 --

Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director ACCESS Newswire 8:30 AM

-- March 12, 2026 --

Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026 ACCESS Newswire 8:00 AM

-- March 10, 2026 --

Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack ACCESS Newswire 8:30 AM

-- March 3, 2026 --

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief ACCESS Newswire 8:00 AM

-- February 25, 2026 --

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship ACCESS Newswire 8:30 AM

-- February 20, 2026 --

Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements ACCESS Newswire 8:00 AM

-- February 19, 2026 --

Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record ACCESS Newswire 8:00 AM

-- February 17, 2026 --

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R)) ACCESS Newswire 8:30 AM

-- February 13, 2026 --

Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors ACCESS Newswire 8:00 AM

-- February 12, 2026 --

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R)) ACCESS Newswire 8:00 AM

-- February 11, 2026 --

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements ACCESS Newswire 7:45 AM

-- February 10, 2026 --

Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement ACCESS Newswire 8:00 AM

-- February 5, 2026 --

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit ACCESS Newswire 8:00 AM

-- February 3, 2026 --

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution ACCESS Newswire 8:00 AM

-- January 29, 2026 --

Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin ACCESS Newswire 8:00 AM

-- January 27, 2026 --

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks ACCESS Newswire 8:00 AM

-- January 22, 2026 --

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity ACCESS Newswire 8:00 AM

-- January 21, 2026 --

Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign ACCESS Newswire 8:00 AM

-- January 20, 2026 --

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief ACCESS Newswire 8:00 AM